Literature DB >> 372207

Abnormal plasma catecholamine responses in acromegalics.

G R Van Loon.   

Abstract

Plasma dopamine, norepinephrine, and epinephrine responses to bromocriptine (2.5 mg orally) or to LRH (100 microgram iv) were studied in seven acromegalic patients. In contrast to normal men, in whom plasma concentrations of catecholamines decrease markedly, acromegalic subjects fail to show decreases in plasma dopamine, norepinephrine, or epinephrine in response to bromocriptine (four of four studied) or LRH (three of four studied). Mean basal plasma catecholamine concentrations do not differ in acromegalic patients, normal men, and a group of nonacromegalic endocrine control patients. Since it appears that bromocriptine and LRH suppress plasma catecholamine concentrations through mechanisms at brain catecholamine neurons, these data are compatible with disordered catecholamine neurons in the brain of patients with acromegaly.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 372207     DOI: 10.1210/jcem-48-5-784

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

2.  Effect of bromocriptine on plasma catecholamines in normal subjects and prolactin-secreting tumor patients.

Authors:  A M Mancini; M Barontini; I Armando; G Levin; A Kleiman; J Razumny; I Molocznik
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

3.  The GH/IGF-1 Axis and Heart Failure.

Authors:  Graziella Castellano; Flora Affuso; Pasquale Di Conza; Serafino Fazio
Journal:  Curr Cardiol Rev       Date:  2009-08

Review 4.  Management of acromegaly: is there a role for primary medical therapy?

Authors:  Zachary M Bush; Mary Lee Vance
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

5.  Adrenal morphology and function in acromegalic patients in relation to disease activity.

Authors:  Alessandro Ciresi; Marco C Amato; Calogero Vetro; Renato Lo Coco; Aldo Galluzzo; Carla Giordano
Journal:  Endocrine       Date:  2009-08-14       Impact factor: 3.633

6.  Altered dopaminergic modulation of sympathetic nervous system activity in idiopathic edema.

Authors:  R A Catania; J R Sowers; N Stern; M L Tuck; J Paris
Journal:  J Endocrinol Invest       Date:  1984-10       Impact factor: 4.256

Review 7.  Pathogenesis and prevalence of hypertension in acromegaly.

Authors:  M Bondanelli; M R Ambrosio; E C degli Uberti
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.